Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Merus Labs International Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10600
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women’s health, urology, and infectious disease. Its products include Salagen, a pilocarpine hydrochloride oral tablet used to manage symptoms of xerostomia associated with radiation therapy; Estraderm, a patch medication containing estrogen, which is used to reduce symptoms of menopause, such as hot flashes and vaginal dryness in women, and others. It operates in Luxembourg, British Columbia, the Netherlands, and the US. The company markets its products in Austria, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Italy, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, Switzerland. Merus Labs International is headquartered in Toronto, Ontario, Canada.

Merus Labs International Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Partnerships 18
Merus Labs Enters into Agreement with Vansen Pharma 18
Equity Offering 19
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Asset Transactions 28
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Acquisition 30
Norgine Acquires Merus Labs International 30
Merus Labs International Inc – Key Competitors 32
Merus Labs International Inc – Key Employees 33
Merus Labs International Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 11, 2017: Merus Labs Reports Fiscal Q2 2017 Results 35
Feb 14, 2017: Merus Labs Reports Fiscal Q1 2017 Results 37
Other Significant Developments 40
May 04, 2017: Merus Labs Announces Key Milestone for Sintrom Profit Enhancing Initiative 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Merus Labs International Inc, Pharmaceuticals & Healthcare, Key Facts 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Merus Labs Enters into Agreement with Vansen Pharma 18
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Norgine Acquires Merus Labs International 30
Merus Labs International Inc, Key Competitors 32
Merus Labs International Inc, Key Employees 33
Merus Labs International Inc, Subsidiaries 34

List of Figures
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orlen Upstream Sp zoo:石油・ガス:M&Aディール及び事業提携情報
    Summary Orlen Upstream Sp zoo (Orlen Upstream), a subsidiary of Polski Koncern Naftowy Orlen SA is an oil and gas company that offers petroleum products and natural gas. The company provides products such as motor fuel, diesel, LPG, marine fuel, aviation fuel, greases, kerosene, brake fluids, techni …
  • Daikin Industries Ltd (6367):企業の財務・戦略的SWOT分析
    Daikin Industries Ltd (6367) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Cascadian Therapeutics Inc (CASC):製薬・医療:M&Aディール及び事業提携情報
    Summary Cascadian Therapeutics Inc (Cascadian), formerly Oncothyreon Inc is a clinical-stage biotechnology company that develops therapeutic products for the treatment of cancer. The company’s lead clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule HER2 …
  • Amphastar Pharmaceuticals Inc (AMPH)-製薬・医療分野:企業M&A・提携分析
    Summary Amphastar Pharmaceuticals Inc (Amphastar) is a specialty pharmaceutical company that develops, manufactures and markets generic and proprietary injectable, intranasal and inhalation products. It also sells insulin active pharmaceutical ingredient (insulin API) products. The company’s product …
  • Riverbed Technology Inc:企業の戦略的SWOT分析
    Riverbed Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Nichirei Corporation:企業の戦略・SWOT・財務情報
    Nichirei Corporation - Strategy, SWOT and Corporate Finance Report Summary Nichirei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Promotora y Operadora de Infraestructura, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Promotora y Operadora de Infraestructura, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Promotora y Operadora de Infraestructura, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Teladoc Health Inc (TDOC):企業の財務・戦略的SWOT分析
    Summary Teladoc Health Inc (Teladoc Health), formerly TelaDoc Inc, is a provider of virtual healthcare services for wellness and prevention of acute care and complex healthcare needs. It offers primary care services managing chronic conditions; mental health guidance; personalized digital healthcare …
  • Islet Sciences Inc (ISLT):企業の財務・戦略的SWOT分析
    Summary Islet Sciences Inc (Islet Sciences) is a drug development company that develops medicines and technologies for the treatment of metabolic diseases. The company's pipeline products include immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflamma …
  • Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps …
  • PanOptica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PanOptica Inc (PanOptica) is a clinical-stage biopharmaceutical company that develops topical eye drops for the treatment of sight-threatening eye diseases. The company concentrates on candidates that are at or near the investigational new drug application stage. It develops PAN-90806, a nov …
  • Packaging Corporation of America:企業の戦略・SWOT・財務情報
    Packaging Corporation of America - Strategy, SWOT and Corporate Finance Report Summary Packaging Corporation of America - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Denbury Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Denbury Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Denbury Resources Inc (Denbury) is an independent oil and natural gas company. It carries out exploration, development and production of oil and natural gas from its assets in the Gulf Coast an …
  • Consumers Energy Co (CMS PR B):石油・ガス:M&Aディール及び事業提携情報
    Summary Consumers Energy Co (Consumers), formerly Consumers Power, is an electric and natural gas utility. The company generates purchases, transmits, distributes, and sells electricity. It also carries out the purchase, transmission, storage, distribution, and sale of natural gas. It generates elec …
  • Independent News & Media PLC (IPDC):企業の財務・戦略的SWOT分析
    Independent News & Media PLC (IPDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • iRhythm Technologies Inc (IRTC):企業の財務・戦略的SWOT分析
    iRhythm Technologies Inc (IRTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Biosense Webster Inc-医療機器分野:企業M&A・提携分析
    Summary Biosense Webster Inc (Biosense Webster), a subsidiary of Johnson & Johnson is a medical device company that offers cardiac arrhythmias products. The company designs, manufactures and markets products for diagnosis and treatment of cardiac arrhythmias. Its products comprise ablation catheters …
  • Huaneng Power International, Inc.:企業の戦略・SWOT・財務情報
    Huaneng Power International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Huaneng Power International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Bioorganic Research and Services SA (BNT):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioorganic Research and Services SA (Bionaturis) is a biotechnology company that develops non-prescription products for production animals and pets. The company offers products such as BNT006, BNT007, BNT010, BNT015 and BNT005. It provides non-therapeutic and therapeutic products for poultry …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆